Our proposal suggests that the expression level of AIM2 could be a useful factor in categorizing IBD patients, and that patients with a high expression of AIM2 may not be suitable candidates for anti-TNF treatment. The gene discussed is AIM2; the disease is inflammatory bowel disease.